Evidence map›Paper›PMID 33681163›Full record

ArticleFrontiers in bioengineering and biotechnology2021

Wenbo Liu, Xin Wang, Jinlei Su, Qingsong Jiang, Jing Wang, Yang Xu, Yudong Zheng, Zhihui Zhong, Hai Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. AnFrontiers in surgery · 2024
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenbo LiuSchool of Material Science and Engineering, University of Science and Technology Beijing, Beijing, China.
Xin WangLaboratory of Nonhuman Primate Disease Modeling Research, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Jinlei SuNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, China.
Qingsong JiangNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, China.
Jing WangNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, China.
Yang XuNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, China.
Yudong ZhengSchool of Material Science and Engineering, University of Science and Technology Beijing, Beijing, China.
Zhihui ZhongLaboratory of Nonhuman Primate Disease Modeling Research, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Hai LinNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dura substitutes are applied in duraplasty to repair lost or damaged dura. Collagen-based dura substitutes are mainstream products in both the US and Chinese markets. In this study, dura substitute devices with potential dura regeneration ability are evaluated. The dura substitutes are composed of fibrous type I collagen that were purified from bovine tendon. Physical and chemical characterization demonstrated that the tested dura substitute has desirable porous scaffolding structures and is composed of highly purified type I collagen. The collagen dura substitutes were further investigated

Indexed as

animal studycollagendura substitutepreclinical (in vivo) studiessafety and efficacy

Identifiers

PMID33681163
PMCPMC7930396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.